An 8 Week, Randomized, Double-Blind, Parallel Group, Multicenter Trial Comparing the Efficacy and Safety of Oral IPL512,602 [Inflazyme Pharmaceuticals] to Placebo in Subjects With Moderate to Severe Persistent Asthma Inadequately Controlled on Inhaled Corticosteroids
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2014
At a glance
- Drugs IPL 512602 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms CAPSICS
- Sponsors Inflazyme Pharmaceuticals
- 24 Apr 2014 Last checked against ClinicalTrial.gov record.
- 24 Jan 2006 New trial record.